SOPHiA GENETICS SA (NASDAQ:SOPH – Get Free Report) Chairman Jurgi Camblong sold 20,000 shares of the stock in a transaction that occurred on Tuesday, August 4th. The shares were sold at an average price of $6.92, for a total transaction of $138,400.00. Following the sale, the chairman directly owned 3,472,822 shares of the company’s stock, valued at $24,031,928.24. This represents a 0.57% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Jurgi Camblong also recently made the following trade(s):
- On Tuesday, July 21st, Jurgi Camblong sold 20,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $6.63, for a total transaction of $132,600.00.
- On Monday, July 20th, Jurgi Camblong sold 24,381 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $6.29, for a total transaction of $153,356.49.
- On Friday, July 10th, Jurgi Camblong sold 8,500 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.62, for a total transaction of $47,770.00.
- On Tuesday, July 7th, Jurgi Camblong sold 17,685 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.28, for a total transaction of $93,376.80.
- On Monday, July 6th, Jurgi Camblong sold 22,486 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.25, for a total transaction of $118,051.50.
- On Thursday, June 25th, Jurgi Camblong sold 1,373 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.70, for a total transaction of $7,826.10.
- On Friday, June 26th, Jurgi Camblong sold 50,069 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.80, for a total value of $290,400.20.
- On Wednesday, June 10th, Jurgi Camblong sold 8,500 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.24, for a total value of $44,540.00.
SOPHiA GENETICS Stock Up 6.2%
Shares of NASDAQ:SOPH opened at $6.69 on Friday. SOPHiA GENETICS SA has a 1 year low of $2.96 and a 1 year high of $7.21. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.69 and a quick ratio of 1.90. The business’s 50-day moving average is $5.57 and its 200-day moving average is $5.13. The company has a market capitalization of $561.22 million, a price-to-earnings ratio of -5.82 and a beta of 0.96.
Key Stories Impacting SOPHiA GENETICS
Here are the key news stories impacting SOPHiA GENETICS this week:
- Positive Sentiment: SOPHiA GENETICS raised its 2026 revenue outlook to $94 million–$96 million, implying 22%–24% year-over-year growth and exceeding the roughly $93.4 million consensus estimate. Management continues to target adjusted EBITDA breakeven by year-end. 2026 revenue outlook article
- Positive Sentiment: The company entered a multi-year global collaboration with AstraZeneca to develop, validate and commercialize two companion diagnostics for precision-oncology therapies. The partnership could expand SOPH’s commercial reach and provide longer-term growth opportunities. SOPHiA GENETICS AstraZeneca partnership article
- Positive Sentiment: HC Wainwright maintained a Buy rating and raised its price target from $12 to $14. BTIG Research also maintained a Buy rating and lifted its target from $8 to $9, signaling improved confidence in the company’s growth prospects.
- Positive Sentiment: Second-quarter revenue rose 27% year over year to $23.31 million, surpassing the $21.72 million consensus estimate. The adjusted EBITDA loss also improved by 27% to $8.8 million.
- Neutral Sentiment: HC Wainwright reduced its FY2029 EPS estimate to $0.31 from $0.34 but increased its FY2030 forecast to $0.72 from $0.69. The firm’s $14 target and Buy rating were unchanged, suggesting near-term forecast pressure but stronger longer-term expectations.
- Neutral Sentiment: Chairman Jurgi Camblong, CTO Abhimanyu Verma and insider Zhenyu Xu sold a combined 35,000 shares for approximately $242,350 under pre-arranged Rule 10b5-1 plans. Their remaining ownership stakes declined only modestly, reducing the significance of the sales as a bearish signal.
- Negative Sentiment: SOPH reported a quarterly loss of $0.26 per share, worse than the expected $0.21 loss. The company remains deeply unprofitable, with a negative net margin and analysts forecasting a full-year loss of approximately $0.58 per share.
Hedge Funds Weigh In On SOPHiA GENETICS
Several large investors have recently added to or reduced their stakes in the business. 1492 Capital Management LLC bought a new position in shares of SOPHiA GENETICS in the fourth quarter valued at approximately $973,000. Royce & Associates LP bought a new stake in SOPHiA GENETICS during the fourth quarter worth $2,009,000. Hodges Capital Management Inc. purchased a new stake in SOPHiA GENETICS in the 1st quarter valued at $2,157,000. Royal Bank of Canada raised its position in SOPHiA GENETICS by 3,130.2% in the 1st quarter. Royal Bank of Canada now owns 19,381 shares of the company’s stock valued at $96,000 after buying an additional 18,781 shares during the last quarter. Finally, Sei Investments Co. bought a new position in SOPHiA GENETICS during the 1st quarter valued at $1,772,000. Institutional investors own 31.59% of the company’s stock.
Wall Street Analyst Weigh In
SOPH has been the subject of a number of research reports. BTIG Research raised their price target on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a “buy” rating in a report on Wednesday. Zacks Research upgraded shares of SOPHiA GENETICS to a “hold” rating in a report on Tuesday, July 21st. Weiss Ratings reissued a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Friday, July 17th. Finally, HC Wainwright boosted their target price on SOPHiA GENETICS from $12.00 to $14.00 and gave the company a “buy” rating in a research report on Wednesday. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $10.00.
View Our Latest Report on SOPH
SOPHiA GENETICS Company Profile
SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.
The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.
Read More
- Five stocks we like better than SOPHiA GENETICS
- Sandisk Just Delivered a Blowout Quarter—Here’s Why the Stock Is Falling
- 4 Oil and Gas ETF Plays as Prices Stay Sky-High
- What Tesla Stands to Lose If It Walks Away From China
- Disney Sets Up for a Magical Year in 2027
Receive News & Ratings for SOPHiA GENETICS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SOPHiA GENETICS and related companies with MarketBeat.com's FREE daily email newsletter.
